MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?

References

• Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7(8):585-98
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-60
   PubMed Web of Science ®Google Scholar
• Ghiso E, Giordano S. Targeting MET: why, where and how? Curr Opin Pharmacol 2013;13:511-18
   PubMed Web of Science ®Google Scholar
• Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41
   PubMed Web of Science ®Google Scholar
• Derksen PW, Keehnen RM, Evers LM, et al. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002;99:1405-10
   PubMed Web of Science ®Google Scholar
• Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48
   PubMed Web of Science ®Google Scholar
• Graveel CR, Tolbert D, Vande Woude GF. MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 2013;5:7
   PubMedGoogle Scholar
• Rosário M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003;13:328-35
   PubMed Web of Science ®Google Scholar
• Schaeper U, Gehring NH, Fuchs KP, et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 2000;149:1419-32
   PubMed Web of Science ®Google Scholar
• Lamorte L, Rodrigues S, Naujokas M, et al. Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program. J Biol Chem 2002;277:37904-11
   PubMedGoogle Scholar
• Saucier C, Khoury H, Lai KM, et al. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci USA 2004;101:2345-50
   PubMed Web of Science ®Google Scholar
• Weimar IS, Miranda N, Muller EJ, et al. Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp Hematol 1998;26:885-94
   PubMed Web of Science ®Google Scholar
• Mahtouk K, Tjin EP, Spaargaren M, et al. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 2010;1806:208-19
   PubMed Web of Science ®Google Scholar
• Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010;46:1260-70
   PubMed Web of Science ®Google Scholar
• Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011;29(36):4789-95
   PubMed Web of Science ®Google Scholar
• Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29(36):4803-10
   PubMed Web of Science ®Google Scholar
• Mariani M, McHugh M, Petrillo M, et al. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget 2014;5(13):4855-67
   PubMedGoogle Scholar
• Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011;3:S21-35
   PubMedGoogle Scholar
• Prat M, Oltolina F and Basilico C. Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy. Biomedicines 2014;2:359-83
   PubMedGoogle Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and rogress. Nat Rev Cancer 2012;12:89-103
   PubMed Web of Science ®Google Scholar
• Liu L, Zeng W, Wortinger MA, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res 2014;20:6059-70
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Palmieri D, et al. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci USA 2013;110:8573-8
   PubMed Web of Science ®Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61
   PubMed Web of Science ®Google Scholar
• Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet 2014; pii:S0140-6736(14)60493-1
   PubMedGoogle Scholar
• Rocci A, Hofmeister CC, Pichiorri F. The potential of miRNAs as biomarkers for multiple myeloma. Expert Rev Mol Diagn 2014;14(8):947-59
   PubMed Web of Science ®Google Scholar
• Gambella M, Rocci A, Passera R, et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica 2014;99(2):e14-16
   Google Scholar
• Börset M, Hjorth-Hansen H, Seidel C, et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998-4004
   PubMed Web of Science ®Google Scholar
• Borset M, Lien E, Espevik T, et al. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996;271:24655-61
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57
   PubMed Web of Science ®Google Scholar
• Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006;108:2755-63
   PubMed Web of Science ®Google Scholar
• Seidel C, Lenhoff S, Brabrand S, et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002;119:672-6
   PubMedGoogle Scholar
• Wader KF, Fagerli UM, Holt RU, et al. Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur J Haematol 2008;81:380-3
   PubMedGoogle Scholar
• Tjin EP, Derksen PW, Kataoka H, et al. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 2004;104:2172-5
   PubMedGoogle Scholar
• Wader KF, Fagerli UM, Børset M, et al. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology 2012;60:443-51
   PubMedGoogle Scholar
• Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-16
   PubMed Web of Science ®Google Scholar
• Ria R, Reale A, De Luisi A, et al. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res 2011;1:76-89
   PubMedGoogle Scholar
• Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23
   PubMed Web of Science ®Google Scholar
• Ferrucci A, Moschetta M, Frassanito MA, et al. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clin Cancer Res 2014;20:5796-807
   PubMedGoogle Scholar
• Stellrecht CM, Phillip CJ, Cervantes-Gomez F, et al. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 2007;67:9913-20
   PubMed Web of Science ®Google Scholar
• Hov H, Holt RU, Rø TB, et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2004;10:6686-94
   PubMedGoogle Scholar
• Holt RU, Fagerli UM, Baykov V, et al. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 2008;93:619-22
   PubMed Web of Science ®Google Scholar
• Hov H, Tian E, Holien T, et al. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol 2009;82:277-87
   PubMedGoogle Scholar
• Manier S, Sacco A, Leleu X, et al. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012;2012:157496
   PubMed Web of Science ®Google Scholar
• Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007;109:3024-30
   PubMed Web of Science ®Google Scholar
• Kristensen IB, Christensen JH, Lyng MB, et al. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol 2013;161:373-82
   PubMed Web of Science ®Google Scholar
• Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1996;93:7644-8
   PubMed Web of Science ®Google Scholar
• Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999;94:3883-8
   PubMed Web of Science ®Google Scholar
• Seidel C1, Børset M, Turesson I, et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91:806-12
   PubMed Web of Science ®Google Scholar
• Rocci A, Gambella M, Aschero S, et al. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol 2014;164:841-50
   PubMedGoogle Scholar
• Ludek P, Hana S, Zdenek A, et al. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 2010;84:332-6
   PubMedGoogle Scholar
• Wader KF, Fagerli UM, Holt RU, et al. Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters. Eur J Haematol 2011;87:394-9
   PubMed Web of Science ®Google Scholar
• Bardella C, Dettori D, Olivero M, et al. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007;13:2191-8
   PubMedGoogle Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308
   PubMed Web of Science ®Google Scholar
• Moschetta M, Basile A, Ferrucci A, et al. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res 2013;19:4371-82
   PubMed Web of Science ®Google Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88
   PubMed Web of Science ®Google Scholar
• Que W, Chen J, Chuang M, et al. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 2012;120:195-203
   PubMedGoogle Scholar
• Que W, Chen J. Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep 2011;4:343-9
   PubMedGoogle Scholar
• Wang H, Baladandayuthapani V, Lin HY, et al. Mucin 20 (MUC20) Modulates Proteasome Assembly Chaperones through the c-MET Pathway and Is a Biomarker of Proteasome Inhibitor Sensitivity in Myeloma. 57th ASH Annual Meeting & Exposition, San Francisco 2014
   Google Scholar
• Rampa C, Tian E, Våtsveen TK, et al. Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients. Biomark Res 2014;2:8
   PubMedGoogle Scholar
• Phillip CJ, Zaman S, Shentu S, et al. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 2013;6:92
   PubMedGoogle Scholar
• Minuti G, Cappuzzo F, Duchnowska R, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 2012;107:793-9
   PubMedGoogle Scholar
• Koeppen H, Yu W, Zha J, et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014;20:4488-98
   PubMed Web of Science ®Google Scholar
• Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-37
   PubMed Web of Science ®Google Scholar
• Michieli P, Basilico C, Pennacchietti S. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET-response. Clin Cancer Res 2013;19(15):4291
   PubMedGoogle Scholar
• Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:1544-53
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Zaman S, Thomas SK, et al. Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM). 56th ASH Annual Meeting & Exposition, New Orleans,2013
   Google Scholar
• Patnaik A, Weiss GJ, Papadopoulos KP, et al. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer 2014;111(2):272-80
   PubMed Web of Science ®Google Scholar
• Aftab DT, Suominen MI, Clary DO, et al. Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model. 57th ASH Annual Meeting & Exposition, San Francisco 2014
   Google Scholar
• Du W, Hattori Y, Yamada T, et al. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007;109:3042-9
   PubMed Web of Science ®Google Scholar
• Slørdahl TS, Denayer T, Moen SH, et al. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment. Eur J Haematol 2013;91:399-410
   PubMedGoogle Scholar
• Zhu K, Kong X, Zhao D, et al. c-MET kinase inhibitors: a patent review (2011 - 2013). Expert Opin Ther Pat 2014;24:217-30
   PubMed Web of Science ®Google Scholar